Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)

Published on October 21, 2021

The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.

Continue reading on website
Other news

Diversity is not a seasonality

October 21, 2021
It is necessary to promote the attraction of diverse talent, provide adequate spaces to enhance their development, and make visible their opinions and needs in terms of labor rights

Roche's (RHHBY) Tecentriq Gets FDA Nod for Another Indication (Revised)

October 21, 2021
Roche (RHHBY) immuno-oncology drug Tecentriq gets FDA approval for yet another indication of lung cancer.